Source: 3 Former Obama US CMS Officials Being Considered To Lead Biden’s Medicare Agency

The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.

From left, Chiquita Brooks-LaSure, Andy Slavitt and Jon Blum are being considered as CMS administrator, Medtech Insight has learned.
From left, Chiquita Brooks-LaSure, Andy Slavitt and Jon Blum are being considered as CMS administrator, Medtech Insight has learned • Source: Manatt/CMS

When it comes to the question of who should succeed Seema Verma as head of the US Centers for Medicare and Medicaid Services (CMS), the chatter seems to be centered around three individuals who previously served at the agency under the Obama administration, a source with knowledge of the discussions told Medtech Insight.

More from Leadership

HHS Has ‘Utterly Failed,’ Kennedy Advisor Argues

 
• By 

Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.

Some Staff Say Makary’s First Speech To FDA Off-Target Despite Science Focus

 

Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.

Dexcom’s Jake Leach And Adrian Gut Discuss Strategy For CGM Growth, Reimbursement, AI Integration And Policy Challenges

 
• By 

In an interview with Medtech Insight, Dexcom’s COO Jake Leach and Adrian Gut, senior director international access, discuss the company’s global expansion, the role of AI in diabetes management, the challenges of securing reimbursement, and how regulators are influencing the future of CGM technology.

LSI 2025: Vektor Medical CEO Says ‘Arrhythmia Is The Biggest Health Care Crisis Nobody Talks About,’ vMap Treats It With 91.1% Accuracy

 
• By 

Vektor Medical is ramping up efforts to bring its vMap technology used to identify arrhythmia sources to more US hospitals, start enrollment in a multinational trial, and commercialize in Europe, pending the CE mark. Medtech Insight sat down with CEO Rob Krummen at LSI 2025 to discuss their plans.

More from Medtech Insight

Medtech Industry Faces Tariffs Despite Pleas for Exemption

 
• By 

Medical devices, diagnostics, and equipment face tariffs announced by President Donald Trump, despite industry pleas for exemption. The tariffs, ranging from 10%-49%, impact most countries trading with the US, potentially hindering innovation and increasing costs in the medtech sector.

FDA Scrubs ‘Gender’ From Final Guidance On Sex-Specific Data But Encourages More Women In Clinical Trials

 

The US FDA has published its final document to guide sponsors on using sex-specific data in designing clinical trials of medical devices. However, the guidance removes all references to gender that appeared in January’s draft guidance, released before the Trump administration took office.